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Background:Osimertinib, a 3rd-generation EGFR-TKI selective for both sensitising
and EGFR T790M resistance mutations, has shown efficacy in pts with CNSmetastases;
encouraging activity has been reported in pts with LM at 160mg once daily (QD)
(BLOOM; NCT02228369). We report LM activity with osimertinib 80mgQD in pts
with LM from studies across the AURA program (NCT01802632; NCT02094261;
NCT02442349; NCT02151981).
Methods: Pts with EGFR T790M positive advanced NSCLC and progression on EGFR-
TKI received osimertinib 80mgQD. Patients with LM and CNSmetastases were eligi-
ble if asymptomatic and stable. Baseline brain scans were mandated in pts with known
or treated CNSmetastases at study entry; pts with evidence of LM by neuroradiological
blinded independent review (BICR) were included for retrospective analysis. Follow-
up brain scans were assessed for radiologic LM response by LM BICR per Response
Assessment in Neuro-Oncology LM criteria. LM objective response rate (ORR), LM
duration of response (DoR), LM progression-free survival (PFS) and overall survival
(OS) were assessed retrospectively. Results are based on individual data cutoffs for each
study. A longitudinal analysis overlaid changes from baseline non-CNS tumour size
with LM responses at each visit for AURA LM and BLOOM LMpts.
Results: 22 LM pts from the AURA studies were included for analysis. Median treat-
ment exposure was 7.3mo (range 2.3–16.5). Baseline characteristics were broadly con-
sistent with the overall AURA study population: median age 58 yrs; female 59%; Asian
82%;WHOPS 1 82%. LMORRwas 55% (95%CI 32, 76); complete or partial LM
response reported in 6 pts (27%) each. Median LMDoRwas not reached (95% CI 2.8,
not calculable [NC]). Median LM PFS was 11.1mo (95%CI 4.6, NC). OS was 18.8mo
(95%CI 6.3, NC). Graphical assessment of longitudinal analysis showed similar non-
CNS and LM responses in AURA LM and BLOOMLMpts.
Conclusions: Consistent with early efficacy outputs from BLOOM (160mgQD), osi-
mertinib 80mgQD showed a clinically meaningful benefit in pts with T790M-positive
NSCLC and radiographically-detected LM. Additional studies are needed to further
evaluate the CNS efficacy of osimertinib 80mgQD in pts with EGFRmNSCLC and
LM.
Clinical trial identification: AURA extension (NCT01802632), AURA2
(NCT02094261), AURA3 (NCT02151981), AURA17 (NCT02442349).
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